Forbion European Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to identify opportunities in the life sciences industry in Europe. The company was incorporated in 2021 and is based in Wilmington, Delaware.
IPO Year: 2022
Exchange: NASDAQ
Website: https://forbion.com/en/feac/
| Date | Price Target | Rating | Analyst |
|---|
15-12G - Forbion European Acquisition Corp. (0001874495) (Filer)
8-K - Forbion European Acquisition Corp. (0001874495) (Filer)
25-NSE - Forbion European Acquisition Corp. (0001874495) (Subject)
10-Q - Forbion European Acquisition Corp. (0001874495) (Filer)
8-K - Forbion European Acquisition Corp. (0001874495) (Filer)
DEFA14A - Forbion European Acquisition Corp. (0001874495) (Filer)
DEFM14A - Forbion European Acquisition Corp. (0001874495) (Filer)
8-K - Forbion European Acquisition Corp. (0001874495) (Filer)
425 - Forbion European Acquisition Corp. (0001874495) (Subject)
8-K - Forbion European Acquisition Corp. (0001874495) (Filer)
Fastest customizable press release news feed in the world
BOSTON and MONTREAL, Sept. 7, 2023 /PRNewswire/ - enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs, today announced the appointment of Richard Bryce, MBChB, MRCGP, MFPM as its Chief Medical Officer, effective September 19, 2023. Dr. Bryce will oversee the clinical development of EG-70, enGene's lead product candidate for non-muscle invasive bladder cancer (NMIBC), as well as the development strategy for enGene's therapeutic pipeline of tissue-targeted non-viral gene therapies.
Leading institutional investors commit $135 million USD in transaction financing, anchored by FEAC's sponsor, Forbion Growth Sponsor FEAC I B.V. (together with its parent entity Forbion Growth Opportunities Fund I Cooperatief U.A., "Forbion Growth").enGene is a clinical-stage biotechnology company developing non-viral gene therapies based on its proprietary dually derivatized chitosan ("DDX") platform that are re-dosable, manufacturable at scale and designed to be seamlessly integrated into community clinical practices across the globe.Net proceeds are expected to be used to finance enGene's operations through multiple potential value inflection milestones towards a potential Biologics Licen
BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter Joustra was elected as a new member of the Board of Directors at the Extraordinary General Meeting held on December 9, 2022. Mr. Wouter Joustra brings a breadth of capital markets and investment experience in the life sciences investment industry to VectivBio. He joined Forbion, a leading European life sciences venture capital firm, in October 2019, where he is currently General Partner. At Forbion, Mr. Joustra is responsible for deal originatio
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Forbion European Acquisition Corp. (0001874495) (Issuer)
4 - Forbion European Acquisition Corp. (0001874495) (Issuer)
3/A - Forbion European Acquisition Corp. (0001874495) (Issuer)
3/A - Forbion European Acquisition Corp. (0001874495) (Issuer)
Live Leadership Updates
BOSTON and MONTREAL, Sept. 7, 2023 /PRNewswire/ - enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs, today announced the appointment of Richard Bryce, MBChB, MRCGP, MFPM as its Chief Medical Officer, effective September 19, 2023. Dr. Bryce will oversee the clinical development of EG-70, enGene's lead product candidate for non-muscle invasive bladder cancer (NMIBC), as well as the development strategy for enGene's therapeutic pipeline of tissue-targeted non-viral gene therapies.
This live feed shows all institutional transactions in real time.
SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)
SC 13G - Forbion European Acquisition Corp. (0001874495) (Subject)
SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)
SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)
SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)
SC 13G - Forbion European Acquisition Corp. (0001874495) (Subject)
SC 13G - Forbion European Acquisition Corp. (0001874495) (Subject)
SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)
SC 13G - Forbion European Acquisition Corp. (0001874495) (Subject)
SC 13D - Forbion European Acquisition Corp. (0001874495) (Subject)